Chromatin’s stained glass
Reini Luco and her research team are looking for novel mechanisms of alternative splicing regulation amongst chromatin and long non-coding RNAs. By using a well established and inducible human model system of cell reprogramming, they aim at understanding which is the dynamic interplay between chromatin, lncRNAs and alternative splicing regulation and to demonstrate for the first time the real physiological impact of chromatin on cell-specific splicing.
Alternative splicing is one of the most general and important biological processes in the eukaryotic cell. It affects more than 90% of human genes, it is essential for protein diversity and any misregulation of the highly tissue-specific alternative splicing programs can lead to disease, such as cancer. However the mechanisms of cell-specific alternative splicing regulation are still largely unknown. Unexpectedly, in the past 15 years, chromatin and epigenetic modifications have been shown to play an important role in the regulation of alternative splicing.
In particular, we have shown that non-coding RNAs and histone marks can talk to the splicing machinery via recruitment of chromatin/splicing-adaptor complexes.
Our group aims at the better understanding of the role of epigenetics and long non-coding RNAs in the onset and maintenance of tissue-specific splicing programs, using as an inducible cell reprogramming model system the epithelial-to-mesenchymal transition (EMT). For that purpose we will use state-of-the-art genome-wide deep sequencing approaches, combined with classical molecular and cell biology tools, to depict the molecular mechanisms of regulation of tissue-specific alternative splicing in a cancer-relevant model system.
• 2013: Appointed Group Leader (CNRS-CR1, permanent position), IGH, Montpellier, France
• 2007-2012: Postdoctoral fellow, National Institutes of Health, National Cancer Institute, Bethesda, USA. Tom Misteli’s Lab
• 2007 PhD, Hospital Clinic de Barcelona, Barcelona, Spain. Jorge Ferrer’s Lab
• CNRS Bronze Medal, 2016
• Member of Montpellier’s Laboratories of Excellence: LABEX EpiGenMed, 2014
• Marie Curie Career Integration Grant, 2013
• Member of the EpiGeneSys ”Research Integrating System Biology and Epigenetics”, 2013
• Laureate of the ATIP-AVENIR programme of excellence, 2013
• The Center for Cancer Research top Science advances award, National Institutes of Health, 2011
• NCI Intramural Career Development Innovation Award, National Institutes of Health, 2010
Nov 2016, Nat Struct Mol Biol
May 2015, Nat Struct Mol Biol
Aug 2011, Curr Opin Genet Dev
Jan 2011, Cell
Feb 2010, Science